Literature DB >> 6843110

Protection of thermochemotherapeutic-induced lethal acute hepatic necrosis in the rat by 16,16-dimethyl prostaglandin E2.

M Miyazaki, L Makowka, R E Falk, J A Falk, M McDonell, D Venturi.   

Abstract

These studies further evaluate the hepatocytoprotective properties of 16,16-dimethyl prostaglandin E2 (dmPGE2) by assessing its effect on survival, liver function, and hepatic regeneration in a model of in vivo isolated perfusion of the rat liver with high concentrations of cytotoxic drugs and regional hyperthermia. Isolated perfusion with 1.0 g/kg of 5-FU or hyperthermia of 41 degrees C X 10 min resulted in 90-100% mortality in control rats, with extensive, patchy necrosis and infarction on histologic examination, and markedly elevated levels of SGOT and SGPT at 24 hr after perfusion. Pretreatment with dmPGE2 (10 micrograms/kg sc) at 30 min before, and at 6 and 24 hr after hepatic perfusion significantly improved survival to 80% (P less than 0.01) following 5-FU perfusion and to 40% (P less than 0.05) following hyperthermic perfusion. Animals were followed for at least 21 days after perfusion and demonstrated normal liver histology, dmPGE2-treated rats demonstrated significantly lower SGOT and SGPT levels at 24 hr after perfusion. dmPGE2 (2 micrograms/kg sc) given as above improved the length of time of survival but eventual mortality was not significantly improved. Oral administration (50 micrograms/kg po at 30 min before, 6 and 24 hr after perfusion) and posttreatment (10 micrograms/kg sc at 1, 6, and 24 hr after perfusion) had no significant effect on survival. Hepatic regenerative capacity following partial hepatectomy was severely suppressed following isolated hyperthermochemotherapeutic hepatic perfusion. Pretreatment with dmPGE2 (10 micrograms/kg sc) restored the DNA synthetic response in perfused rats to that seen in normal control rats after partial hepatectomy (P less than 0.05 and P less than 0.01). The results from these studies further confirm the role of dmPGE2 as a hepatocytoprotective agent and suggest potential clinical application in situations where there has been deliberate, therapeutic insult to the liver.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6843110     DOI: 10.1016/0022-4804(83)90090-2

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

Review 1.  Animal models of fulminant hepatic failure.

Authors:  J Terblanche; R Hickman
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

2.  Effect of administration of fibronectin or aprotinin on liver regeneration after experimental hepatectomy.

Authors:  A H Kwon; S Uetsuji; M Yamamura; K Hioki; M Yamamoto
Journal:  Ann Surg       Date:  1990-03       Impact factor: 12.969

Review 3.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

4.  Interactions between cyclosporin A, indomethacin and 16,16-dimethyl prostaglandin E2: effects on renal, hepatic and gastrointestinal toxicity in the rat.

Authors:  P H Whiting; N Barnard; A Neilsch; J G Simpson; M D Burke
Journal:  Br J Exp Pathol       Date:  1987-12

5.  An in vitro evaluation of prostaglandin E1 and I2 on hypothermic injury to immature myocytes.

Authors:  H Orita; M Fukasawa; K Inui; S Hirooka; H Uchino; K Fukui; M Kohi; M Washio
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

6.  Misoprostol hepatoprotection against ischemia-reperfusion-induced liver injury in the rat.

Authors:  S P Lim; F J Andrews; C Christophi; P E O'Brien
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

Review 7.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

Review 8.  Liver cytoprotection by prostaglandins.

Authors:  J Quiroga; J Prieto
Journal:  Pharmacol Ther       Date:  1993       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.